UnitedHealth Group consolidates near $365.88, after raising 2025 profit outlook

Traders Union
All News
Financial News
UnitedHealth slides 0.08% to $365.88 today

Highlights

UnitedHealth Group reported third-quarter 2025 revenues of $113.2 billion, up 12% year-over-year, and raised its full-year earnings outlook to at least $14.90 per share.
UNH shares closed at $365.88, above the MA-20 ($359.77) and MA-50 ($339.59) but below the MA-200 ($390.01), signaling medium-term bullish momentum but longer-term resistance.
Despite strong daily MACD, mixed momentum and oscillators, high intraday volatility, and a projected five-day range of $374.74–$379.34, the probability of price increase is below 20%.

Earnings outlook raised as revenue growth fuels sentiment shift

UnitedHealth Group reported strong third-quarter results on October 28, 2025, with revenues reaching $113.2 billion, an increase of 12% year-over-year. Earnings per share were $2.59, and adjusted earnings totaled $2.92 per share. The company also raised its full-year 2025 earnings outlook to at least $14.90 per share, reflecting ongoing growth momentum.

Mixed momentum and range-bound action as support meets downside pressure

The price of UNH at $365.88 sits above both the MA-20 ($359.77) and MA-50 ($339.59) but remains below the MA-200 ($390.01), supporting short- and medium-term bullish momentum while still facing a longer-term bearish obstacle. The nearest dynamic support is the Ichimoku Kijun line at $354.41, with resistance to watch at the MA-200 ($390.01). Momentum signals are mixed: daily MACD remains strongly bullish while the ADX indicates a prevailing selling trend. There are no major overbought or oversold signals on daily RSI, Stoch RSI, or CCI, with all sitting in neutral-to-buy territory and BB Power reading as neutral, reflecting indecision among buyers and sellers for the session. The Awesome Oscillator aligns with recent downside pressure, as daily price slipped 0.08% after a noticeable gap up at the open, and the last price is currently near the lower end of today’s range ($358.75 – $377.25). Intraday volatility is high, with trading showing downside pressure after the open. There is a clear divergence between momentum and oscillators, with intraday price action favoring sellers even as medium-term trend indicators stay supportive.

Downside bias as low probability of breakout shapes weekly outlook

For the next five trading days, the projected price range is between $374.74 and $379.34, with an average expected value near $377.04. Based on weekly indicators (1 Buy out of 4), the probability of a price increase is very low (less than 20%), making a decline more likely. In the baseline scenario, price may remain range-bound around current levels. A bullish scenario would require a convincing break above resistance near $390.01, while a bearish scenario would see the stock pushing below short-term support at $354.41, potentially accelerating downside toward the lower end of the recent range.

Viktoras Karapetjanc, expert at Traders Union, sees UnitedHealth Group benefiting from strong quarterly fundamentals and continued revenue growth, supporting a constructive outlook despite mixed short-term technical sentiment. He believes current price action above key moving averages underpins medium-term optimism, though longer-term resistance at $390.01 remains a significant hurdle for sustained upside. The analyst notes that while intraday volatility could favor sellers, underlying momentum, bolstered by upgraded full-year earnings guidance, still provides a solid backdrop. "Continued fundamental strength and improving macro conditions could support a breakout — I remain confident in UNH’s potential if buyers reclaim the $390 level."

Previously it was noted that bullish momentum diverges from overbought signals amid increased volatility in UNH shares. The report also highlighted mixed momentum indicators and a short-term downside bias as institutional activity and earnings anticipation shaped market sentiment.

Source of Data: UNH Price Analysis by TU

The analysis is based on a proprietary model combining technical, on-chain, and expert data. Not investment advice. See methodology

The information is based on forecasts and does not constitute investment advice or a guarantee of future results. Market conditions may change. See our Disclaimer and Editorial Integrity for details.